Our Vision

Our vision at Synjectos VN LLC is to provide to surgeons, hospitals and patients treatment solutions of the state of the art and beyond that through permanent further training and consultancy of internationally respected surgeons.


Synjectos is the starting product to be sold by Synjectos VN LLC. Synjectos is a “Asian 5” registered all-in-one Bone Substitute Material, which is Calcium-Magnesium-Phosphate (CPC) based, with the potential to be resorbed and replaced by the patient`s own bone, while embedded into the biological remodeling process of bone.

Bone substitute materials become more and more important due to the permanent higher mobility of people causing a higher rate of severe accidents associated with high impact trauma, resulting in tissue and bone damage.

Especially in case of joint related fractures, depression of the articular surface will cause incongruency of the affected joint, resulting in chronic constraints and arthrosis. In such cases it is essential to support the damaged cancellous bone beneath the articular cartilage in order to restore the functionality. Typical indications, but not limited to are: tibia head impression fractures, calcaneal fractures (fxx), proximal fxx of the humerus, but also the filling of bone cysts.

Standard materials to be used in these indications are autograft bone (patients own cancellous bone), but here the availability is limited, it needs a second surgical intervention with some risk for infection, discomfort and risk for morbidity at the donor site. The alternative is allograft or donor bone with additional risk for inherent infectious diseases such as HIV and risk of rejection.

Synjectos, synthetic bone replacement material is of unlimited availability is made of ultrapure raw materials of highest quality with permanent checking of the production process and produced due to ISO 13485. A main part of the raw material is manufactured in Germany and the finished good is made in Vietnam under highest standards. Synjectos VN LLC will bring in international knowledge of treatment options by surgeons training.

Further outlines:
Synjectos VN LLC will develop new products which are already in the pipeline and patents are already submitted. These products aim towards the treatment of infected bone due to open bone fractures most often unsatisfactorily treated by systemic antibiotic treatment only. Here Synjectos VN LLC will offer different carrier materials, which will allow well targeted onsite therapeutic carrier materials and fixed formulation materials with high drug releasing capacity to act as a limb preservative alternative treatment.
Furthermore Synjectos VN LLC will act as a hub for well known manufactures of medical devices and instruments and will provide it´s distribution network for international medical device companies.